Articles
  

Effect of Toll-Like Receptor 3 Agonists on the Functionality and Metastatic Properties of Breast Cancer Cell Model

Abstract

There exists compelling evidence that Toll-like receptor 3 (TLR3) agonists can directly affect human cancer cells. The aim of this study was to investigate anti-cancer effects of TLR3 agonist in human breast cell line.
We assessed potential effects of poly (A:U) on human breast cell line (MDA-MB-231)  on a dose-response and time-course  basis. Human breast cell line  MDA-MB-231  was treated with different concentrations of poly (A:U) and lipopolysaccharide  (LPS). Then, the following assays were performed on the treated cells: dose-response  and time-course cytotoxicity using colorimetric method; matrix metalloproteinase-2  (MMP-2) activity using gelatin zymography method; apoptosis using annexin-v flowcytometry method; and relative expression of TLR3 and MMP-2 mRNA using reverse transcriptase  polymerase chain reaction (RT-PCR) method. Following treatments, dose- response and time-course cytotoxicity using a colorimetric method, (MMP-2) activity (using gelatin zymography), apoptosis  (using annexin-v flowcytometry method) assays and expression of TLR3 and MMP-2 genes (using PCR method) were performed.
Cytotoxicity and flowcytometry analysis of poly (A:U) showed that poly (A:U) do not have any cytotoxic and apoptotic effects in different concentrations used. MMP-2 activity analysis showed significant decrease in higher concentrations  (50 and 100 µg/ ml) between treated and untreated cells.  Moreover, poly A:U treated cells demonstrated decreased expression of MMP-2 gene in higher concentrations.
Collectively, our data indicated that human breast cancer cell line (MDA-MB-231) was highly responsive to poly (A:U). The antimetastatic effect of direct poly (A:U) and TLR3 interactions in MDA-MB-231 cells could provide new approaches in malignant tumor therapeutic strategy.

1. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13(5):816-25.
2. Huan Yang, Huiqin Zhou, Ping Feng, Xiaoni Zhou, Huiyan Wen, Xiaofang Xie, et al . Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010; 29:92.
3. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74(4):479-85.
4. Matijevic T, Pavelic J. Toll-like receptors: cost or benefit for cancer? Curr Pharm Des 2010; 16(9):1081-90.
5. Mikula I Jr, Pastoreková S, Mikula I Sr. Toll-like receptors in immune response to the viral infections. Acta Virol 2010; 54(4):231-45.
6. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T.TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176(8):4894-901.
7. Kaiser WJ, Kaufman JL, Offermann MK. IFN-{alpha} sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J Immunol 2004; 172(3):1699-710.
8. Ritter M, Mennerich D, Weith A, Seither P.Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR 3 ligand poly (I: C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond)2005; 2:16.
9. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133(6):1869-81.
10. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation- induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008;105(2):652-6.
11. Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, et al. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 2008; 68(2):223-9.
12. Pries R, Hogrefe L, Xie L, Frenzel H, Brocks C, Ditz C,et alB. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008; 21(2):209-15.
13. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13:4565-74.
14. Wolska A, Lech-Mara da E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14(2):248-72.
15. Khan AL, Heys SD, Eremin O. Synthetic polyribonucleotides: current role and potential use in oncological practice. Eur J Surg Oncol 1995; 21(2):224-7.
16. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, et al. Adjuvant treatment with polyadenylic- polyuridylic acid (Polya. Polyu) in operable breast cancer. Lancet 1980; 2(8187):161-4.
17. Kim H, Yang E, Lee J, Kim SH, Shin JS, Park JY, et al.Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. Immunology 2008; 124(4):480-8.
18. Salem ML, Kadima AN, Cole DJ, Gillanders WE.Defining the antigen-specific T-cell response to vaccination and poly (I: C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005; 28(3):220-8.
19. Cui Z, Qiu F. Synthetic double-stranded RNA poly (I: C)as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006; 55(10):1267-79.
20. Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, Moretta L,et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A 2004;101(27):10116-21.
21. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, et al. Toll-like receptor 3 promotes cross- priming to virus-infected cells. Nature 2005;433(7028):887-92.
22. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, et al. TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination. J Immunol 2009;183(6):3634-41.
23. Khorramizadeh MR, Aalizadeh N, Pezeshki M, Ghahary A, Zeraati H, Berahmeh A, et al. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters. Int J Urol 2005; 12(7):637-43.
24. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007; 100(5):1301-12.
25. Jiang Q, Wei H, Tian Z. Poly I: C enhances cycloheximide-induced apoptosis of tumor cells through TLR 3 pathway. BMC Cancer 2008; 8:12.
26. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25(1):9-34.

Files
IssueVol 12, No 2 (2013) QRcode
SectionArticles
Keywords
MDA-MB-231 MMP-2 Poly (A U) TLR3
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Alizadeh N, Amiri MM, Salek Moghadam A, Zarnani AH, Saadat F, Safavifar F, Berahmeh A, Khorramizadeh MR. Effect of Toll-Like Receptor 3 Agonists on the Functionality and Metastatic Properties of Breast Cancer Cell Model. Iran J Allergy Asthma Immunol. 1;12(2):161-167.